retatrutide nash trial vs Tirzepatide (2026): Differences in Weight Loss, Metabol – Revolution Health & Wellness Oligonucleotide therapies for nonalcoholic steatohepatitis:

DOI.org (Crossref) , Endocrine, Metabolic & Immune Disorders Drug Targets , vol

T2: Payer resistance

July 2nd, 2025: Rise in Ozempic Vision Loss Lawsuits Sparks Discussion on Broadening GLP-1 MDL Scope A growing wave of lawsuits is being filed against Novo Nordisk, alleging that its GLP-1 receptor agonist medicationsincluding Ozempic and Wegovycaused permanent vision loss due to non-arteritic anterior ischemic optic neuropathy (NAION)

p upper limit of DRI

Note: If you are taking a GLP-1 medication and experience severe, localized abdominal pain that does not improve, do not assume it is just a side effect

"At one year, weight loss is about 8%, but by three years, it's gone down to 6%," he says